| __timestamp | Ascendis Pharma A/S | Novavax, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 6274000 | 19928000 |
| Thursday, January 1, 2015 | 9415000 | 30842000 |
| Friday, January 1, 2016 | 11504000 | 46527000 |
| Sunday, January 1, 2017 | 13482000 | 34451000 |
| Monday, January 1, 2018 | 25057000 | 34409000 |
| Tuesday, January 1, 2019 | 48473000 | 34417000 |
| Wednesday, January 1, 2020 | 76669000 | 145290000 |
| Friday, January 1, 2021 | 160180000 | 298358000 |
| Saturday, January 1, 2022 | 221227000 | 488691000 |
| Sunday, January 1, 2023 | 264410000 | 468946000 |
| Monday, January 1, 2024 | 284545000 |
Unleashing the power of data
In the ever-evolving world of biotechnology, understanding financial health is crucial. This chart provides a fascinating glimpse into the Selling, General, and Administrative (SG&A) expenses of Ascendis Pharma A/S and Novavax, Inc. over the past decade. From 2014 to 2023, Ascendis Pharma's SG&A costs surged by over 4,100%, reflecting its aggressive growth strategy. Meanwhile, Novavax saw a more modest increase of approximately 2,300%, peaking in 2022. Notably, 2021 marked a pivotal year for both companies, with Novavax's expenses nearly doubling, likely due to its COVID-19 vaccine efforts. Ascendis Pharma, on the other hand, steadily increased its spending, indicating a focus on long-term development. This financial narrative underscores the dynamic strategies of these biotech giants as they navigate the competitive landscape.
Operational Costs Compared: SG&A Analysis of Novo Nordisk A/S and Novavax, Inc.
Gilead Sciences, Inc. vs Novavax, Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Viatris Inc. and Ascendis Pharma A/S
Cost Management Insights: SG&A Expenses for Intra-Cellular Therapies, Inc. and Ascendis Pharma A/S
Breaking Down SG&A Expenses: Walgreens Boots Alliance, Inc. vs Ascendis Pharma A/S
Breaking Down SG&A Expenses: Ascendis Pharma A/S vs Blueprint Medicines Corporation
Who Prioritizes Innovation? R&D Spending Compared for Ascendis Pharma A/S and Novavax, Inc.
Who Optimizes SG&A Costs Better? Grifols, S.A. or Novavax, Inc.
Breaking Down SG&A Expenses: MorphoSys AG vs Novavax, Inc.
Who Optimizes SG&A Costs Better? Arrowhead Pharmaceuticals, Inc. or Novavax, Inc.
Wave Life Sciences Ltd. and Novavax, Inc.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Dynavax Technologies Corporation and Novavax, Inc.